Physician profile
Walter Strash
NPI 1528117140
$85,849.36
in general payments reported to CMS, 2019-2025
40 companies · $9,349 in 2025
The $9,349 reported for 2025 was more than what 96% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,188 · 2020: $2,324 · 2021: $1,501 · 2022: $11K · 2023: $4,268 · 2024: $56K · 2025: $9,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $45K · Debt Forgiveness: $20K · Food and Beverage: $3,389 · Royalty Or License: $1,520 · Travel and Lodging: $293 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $44,600.00 |
| Debt Forgiveness | $20,000.00 |
| Food and Beverage | $3,388.52 |
| Royalty Or License | $1,519.71 |
| Travel and Lodging | $292.67 |
| Education | $102.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequence Lifescience, INC | $30,000.00 | 2024 | |
| Nvision Biomedical Technologies, INC. | $21,004.81 | 2020-2024 | Foot and Ankle, Trigon, Food and Ankle |
| Convatec INC. | $20,026.68 | 2024 | |
| Endo USA, INC. | $7,752.62 | 2025 | |
| Medinc of Texas | $2,202.84 | 2019-2023 | |
| Stryker Corporation | $1,316.87 | 2019-2025 | Augment Injectable, Infinity, Infinity Adaptis |
| Depuy Synthes Sales INC. | $1,253.84 | 2022-2025 | Motoband, Va-Lcp, Crosstie |
| Ortho Solutions INC | $431.85 | 2025 | |
| Mission Medical Distribution, LLC | $214.53 | 2023-2025 | |
| Orthofix Medical, INC. | $209.21 | 2019-2025 | Physio-Stim |
| Nevro Corp. | $160.03 | 2022 | |
| Ossio INC | $131.37 | 2021 | |
| Treace Medical Concepts, INC. | $128.82 | 2024-2025 | |
| Acumed LLC | $112.19 | 2025 | Osteomed, Acumed |
| Horizon Therapeutics Plc | $108.82 | 2022-2023 | Krystexxa |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $85.78 | 2019 | |
| Smith+Nephew, INC. | $83.34 | 2024-2025 | Grafix Pl, Bone Anchors With Arthroscopic Delivery System |
| Wright Medical Technology, INC. | $71.87 | 2019-2020 | |
| Organogenesis INC. | $56.90 | 2022-2025 | Affinity, Simplimax |
| Arteriocyte Medical Systems, INC. | $52.72 | 2019 | |
| Curvebeam LLC | $44.17 | 2023 | |
| Abbvie INC. | $39.94 | 2023 | Dalvance |
| Kerecis Limited | $37.01 | 2020-2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Amgen INC. | $35.11 | 2025 | Krystexxa |
| Mimedx Group, INC. | $31.66 | 2025 | |
| Integra Lifesciences Corporation | $24.14 | 2022 | |
| Medline Industries Lp | $23.93 | 2023 | |
| Ermi LLC | $22.08 | 2021 | |
| Stimlabs LLC | $19.30 | 2025 | Geistlich Derma-Gide |
| Paratek Pharmaceuticals, INC. | $18.95 | 2021 | |
| Metric Medical Devices, INC. | $18.87 | 2020 | |
| Averitas Pharma INC. | $16.62 | 2023 | Qutenza |
| Sebela Pharmaceuticals INC. | $16.25 | 2019 | |
| Heron Therapeutics, INC. | $15.25 | 2025 | Zynrelef |
| Nabriva Therapeutics, Plc | $13.97 | 2022 | |
| Grt US Holding, INC. | $13.89 | 2020 | |
| Medtronic, INC. | $13.71 | 2022 | |
| Bioventus LLC | $13.19 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.18 | 2021 | |
| Reprise Biomedical, INC. | $13.05 | 2025 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Strash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.